Zanidatamab

About

Therapy type: Targeted therapy

Therapy strategy: ER signaling inhibition

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) HER2-positive Intraductal Papillary Neoplasm of the Bile Duct Zanidatamab
EMA (1) FDA (1) HER2-positive Intracholecystic Papillary Neoplasm Zanidatamab
EMA (1) FDA (1) HER2-positive Cholangiocarcinoma Zanidatamab